Direct competitive ELISA based on a monoclonal antibody for detection of aflatoxin B1. Stabilization of ELISA kit components and application to grain samples.

Anal Bioanal Chem

Laboratory of Food Analysis, Group of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000, Ghent, Belgium.

Published: January 2006

A direct competitive enzyme-linked immunosorbent assay (ELISA) based on a monoclonal antibody has been developed and optimized for detection of aflatoxin B1 (AFB1), and an ELISA kit has been designed. This immunoassay was highly specific, sensitive, rapid, simple, and suitable for aflatoxin monitoring. AFB1 concentrations determinable by ELISA ranged from 0.1 to 10 microg L(-1). The IC50 value was 0.62 microg L(-1). Recovery from spiked rice samples averaged between 94 and 113%. The effect of different reagents on the stability of HRP-AFB1 conjugate solution was studied. The performance of a stabilized enzyme tracer in ELISA was determined and compared with that of a freshly prepared control solution of HRP-AFB(1) conjugate. The results showed that stabilizing media containing 0.02% BSA, 0.1% Kathon CG, and 0.05 mol L(-1) calcium chloride in 0.05 mol L(-1) Tris-HCl buffer (pH 7.2) maintained the activity of HRP-AFB1 at a dilution of 1:1000 for a period of at least 12 months at room temperature whereas the reference conjugate solution without the additives lost its activity within a few days. Several additives were tested for their stabilizing effect on a monoclonal antibody (MAb) immobilized on the surface of polystyrene microtitre plates. It was shown that immobilized MAb, treated with post-coating solutions containing PVA, BSA, and combinations of these substances with trehalose, retained its activity for at least 4 months at 4 degrees C, whereas the untreated MAb-coated plate lost its activity within 2 days.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00216-005-0103-9DOI Listing

Publication Analysis

Top Keywords

monoclonal antibody
12
direct competitive
8
elisa based
8
based monoclonal
8
detection aflatoxin
8
elisa kit
8
microg l-1
8
hrp-afb1 conjugate
8
conjugate solution
8
005 mol
8

Similar Publications

Construction of Immune Single Domain Antibodies Library for Development of Specific Nanobodies Using Phage Display Strategy.

Recent Pat Biotechnol

January 2025

Center of Excellence in Recombinant Biopharmaceutical Proteins, Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.

Background: poses a considerable global public health challenge. In Egypt, approximately 60% of the inhabitants in the Northern and Eastern areas of the Nile Delta are affected by this parasite, whereas the Southern region experiences a significantly lower infection rate of 6%.

Aim: Construction of an immune phage display Nbs library based on the VHH framework for selecting -specific Nbs for seeking cost-effective, sensitive, and specific diagnostic tools for rapidly detecting mansoni.

View Article and Find Full Text PDF

Objectives: The feasibility of corticosteroid withdrawal (CW) for Takayasu arteritis (TAK) remains uncertain. Two autoantibodies (Abs) are identified against endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) in TAK, determining its three subgroups. This study aimed to evaluate CW using tocilizumab (TCZ) and its association with the Ab profile.

View Article and Find Full Text PDF

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare complement-driven acquired hemolytic anemia with specific presentations of hemoglobinuria, abdominal pain, fatigue, and thrombosis.

Objective: To review the current therapeutic strategies for PNH, including anti-complement therapy and allogeneic hematopoietic cell transplantation (alloHCT), focusing on the tailoring of the approach to the disease subtype.

Results: The outcome of alloHCT varies depending on disease severity, thrombotic history, and response to prior therapies.

View Article and Find Full Text PDF

Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications.

Antib Ther

January 2025

Department of Microbiology & Immunology and Robarts Research Institute, University of Western Ontario, London, Ontario N6A 5B7, Canada.

Background: Immunomodulatory agents targeting the CD11d/CD18 integrin are in development for the treatment of several pathophysiologies including neurotrauma, sepsis, and atherosclerosis. Murine anti-human CD11d therapeutic antibodies have successfully improved neurological and behavioral recovery in rodent neurotrauma models. Here, we present the progression of CD11d-targeted agents with the development of humanized anti-CD11d monoclonal antibodies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!